Index RUT P/E - EPS (ttm) -0.18 Insider Own 3.38% Shs Outstand 299.04M Perf Week -2.33%
Market Cap 2.71B Forward P/E 26.48 EPS next Y 0.33 Insider Trans -0.30% Shs Float 296.85M Perf Month -7.94%
Income -56.11M PEG - EPS next Q -0.05 Inst Own 97.70% Short Float 5.24% Perf Quarter -10.38%
Sales 528.29M P/S 5.12 EPS this Y 115.91% Inst Trans -1.68% Short Ratio 6.78 Perf Half Y -21.69%
Book/sh 0.65 P/B 13.58 EPS next Y 1061.68% ROA -7.18% Short Interest 15.55M Perf Year -27.37%
Cash/sh 0.81 P/C 10.83 EPS next 5Y - ROE -31.68% 52W Range 8.55 - 12.65 Perf YTD -6.48%
Dividend Est. - P/FCF - EPS past 5Y 34.10% ROI -8.92% 52W High -30.36% Beta 0.75
Dividend TTM - Quick Ratio 2.60 Sales past 5Y 24.32% Gross Margin 88.36% 52W Low 3.10% ATR (14) 0.31
Dividend Ex-Date - Current Ratio 3.39 EPS Y/Y TTM 64.39% Oper. Margin 6.45% RSI (14) 39.39 Volatility 3.26% 3.70%
Employees 499 Debt/Eq 2.29 Sales Y/Y TTM 32.29% Profit Margin -10.62% Recom 1.50 Target Price 16.73
Option/Short Yes / Yes LT Debt/Eq 2.24 EPS Q/Q 142.76% Payout - Rel Volume 0.71 Prev Close 8.89
Sales Surprise 1.24% EPS Surprise 303.23% Sales Q/Q 30.09% Earnings Feb 19 BMO Avg Volume 2.29M Price 8.81
SMA20 -4.09% SMA50 -6.03% SMA200 -14.15% Trades
Volume 1,666,927 Change -0.90%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-13-24 Downgrade Morgan Stanley
Overweight → Equal-Weight
$17 → $12
Sep-06-24 Initiated Jefferies
Buy
$18
May-30-24 Initiated Wells Fargo
Overweight
$18
May-14-24 Upgrade Guggenheim
Neutral → Buy
$13
Dec-19-23 Upgrade Morgan Stanley
Equal-Weight → Overweight
$15 → $20
Sep-09-22 Initiated Morgan Stanley
Equal-Weight
$14
Apr-13-22 Resumed Goldman
Neutral
$11
Jan-14-22 Upgrade SVB Leerink
Mkt Perform → Outperform
$12 → $16
Nov-15-21 Upgrade Stifel
Hold → Buy
$12 → $16
Sep-30-21 Upgrade JP Morgan
Neutral → Overweight
$16
Jul-19-21 Resumed BTIG Research
Buy
$15
May-27-21 Initiated Needham
Hold
May-21-21 Initiated UBS
Buy
$16
Apr-14-21 Upgrade Cantor Fitzgerald
Neutral → Overweight
$17
Mar-02-21 Initiated Stifel
Hold
$13
Feb-12-21 Downgrade JP Morgan
Overweight → Neutral
$19
Feb-12-21 Downgrade Cantor Fitzgerald
Overweight → Neutral
$30 → $17
Dec-28-20 Resumed Cantor Fitzgerald
Overweight
$20 → $30
Dec-10-20 Downgrade Citigroup
Buy → Neutral
$20 → $27
Nov-11-20 Initiated Berenberg
Hold
Show Previous Ratings
Mar-12-25 07:29PM
Feb-27-25 07:00AM
Feb-23-25 01:30PM
Feb-20-25 09:30AM
02:05AM
02:03AM
Loading…
02:03AM
(Thomson Reuters StreetEvents)
Feb-19-25 08:30AM
07:00AM
Feb-17-25 09:16AM
Feb-12-25 10:00AM
Feb-10-25 07:00AM
Feb-03-25 07:00AM
Jan-20-25 02:58PM
Jan-17-25 11:19AM
Jan-12-25 04:00PM
09:35AM
Loading…
09:35AM
Jan-02-25 07:00AM
Dec-13-24 02:10PM
09:50AM
Dec-06-24 11:31AM
Nov-07-24 09:50AM
02:09AM
12:26AM
(Thomson Reuters StreetEvents)
Nov-06-24 08:30PM
08:25AM
07:22AM
(Associated Press Finance)
07:00AM
Nov-04-24 09:55AM
Nov-01-24 07:00AM
Oct-30-24 10:01AM
07:00AM
Loading…
Oct-28-24 07:00AM
Oct-21-24 09:50AM
Oct-18-24 12:20PM
09:55AM
09:55AM
06:41AM
Oct-17-24 11:07AM
07:00AM
Oct-09-24 05:35PM
Oct-07-24 05:02PM
Oct-04-24 07:00AM
Sep-24-24 11:50PM
Sep-03-24 07:46AM
07:05AM
07:00AM
Aug-30-24 07:00AM
Aug-21-24 11:24AM
Aug-09-24 10:31AM
Aug-08-24 09:00PM
08:25AM
07:22AM
(Associated Press Finance)
07:00AM
Jul-30-24 07:00AM
Jun-26-24 09:47AM
Jun-05-24 07:00AM
Jun-04-24 07:00AM
May-24-24 08:30AM
May-14-24 07:15AM
May-10-24 04:03PM
01:10PM
11:33AM
10:46AM
May-09-24 10:30PM
11:56AM
08:26AM
08:25AM
07:21AM
(Associated Press Finance)
07:00AM
May-08-24 07:00AM
May-01-24 10:01AM
07:00AM
Mar-29-24 11:30AM
Mar-26-24 09:53AM
Mar-20-24 07:00AM
Mar-13-24 07:07AM
Mar-06-24 11:56PM
Mar-05-24 01:50PM
(Investor's Business Daily)
Mar-01-24 07:00AM
Feb-29-24 11:25AM
11:23AM
Feb-28-24 11:49PM
(Thomson Reuters StreetEvents) -6.50%
08:20AM
07:32AM
07:00AM
Feb-15-24 07:00AM
Feb-09-24 03:14PM
(Investor's Business Daily)
Feb-08-24 07:00AM
Feb-01-24 07:00AM
Jan-12-24 11:02PM
09:31AM
Jan-08-24 09:40AM
Jan-07-24 04:00PM
Jan-05-24 07:02PM
Jan-03-24 11:46AM
07:00AM
Dec-30-23 09:01AM
Dec-29-23 09:48AM
07:01AM
Dec-24-23 06:17AM
Dec-21-23 05:01AM
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Campbell Bradley L President and CEO Feb 19 '25 Option Exercise 9.03 400 3,612 1,151,057 Feb 21 07:27 PM Campbell Bradley L President and CEO Feb 19 '25 Sale 10.00 400 4,000 1,150,657 Feb 21 07:27 PM BRADLEY CAMPBELL Director Feb 19 '25 Proposed Sale 9.85 400 3,940 Feb 19 04:36 PM Campbell Bradley L President and CEO Dec 02 '24 Option Exercise 8.61 7,500 64,575 894,154 Dec 03 06:12 PM Campbell Bradley L President and CEO Dec 02 '24 Sale 10.02 7,500 75,124 886,654 Dec 03 06:12 PM BRADLEY CAMPBELL Director Dec 02 '24 Proposed Sale 9.98 7,500 74,850 Dec 02 04:43 PM Campbell Bradley L President and CEO Nov 06 '24 Option Exercise 12.28 7,901 97,024 894,555 Nov 07 05:49 PM Campbell Bradley L President and CEO Nov 06 '24 Sale 12.50 7,901 98,800 886,654 Nov 07 05:49 PM BRADLEY CAMPBELL Director Nov 06 '24 Proposed Sale 11.74 7,901 92,758 Nov 06 05:03 PM Campbell Bradley L President and CEO Nov 01 '24 Option Exercise 8.61 7,500 64,575 894,154 Nov 04 06:23 PM Campbell Bradley L President and CEO Nov 01 '24 Sale 11.46 7,500 85,960 886,654 Nov 04 06:23 PM BRADLEY CAMPBELL Director Nov 01 '24 Proposed Sale 11.42 7,500 85,650 Nov 01 04:49 PM Campbell Bradley L President and CEO Oct 01 '24 Option Exercise 8.61 7,500 64,575 894,154 Oct 04 04:05 PM Campbell Bradley L President and CEO Oct 01 '24 Sale 10.60 7,500 79,492 886,654 Oct 04 04:05 PM BRADLEY CAMPBELL Director Oct 01 '24 Proposed Sale 10.68 7,500 80,100 Oct 01 04:35 PM Campbell Bradley L President and CEO Sep 03 '24 Option Exercise 8.61 7,500 64,575 894,154 Sep 05 05:01 PM Campbell Bradley L President and CEO Sep 03 '24 Sale 11.71 7,500 87,798 886,654 Sep 05 05:01 PM BRADLEY CAMPBELL Director Sep 03 '24 Proposed Sale 11.61 7,500 87,075 Sep 03 04:19 PM Campbell Bradley L President and CEO Aug 01 '24 Option Exercise 8.61 7,500 64,575 894,154 Aug 05 08:10 PM Campbell Bradley L President and CEO Aug 01 '24 Sale 10.34 7,500 77,518 886,654 Aug 05 08:10 PM BRADLEY CAMPBELL Director Aug 01 '24 Proposed Sale 10.31 7,500 77,325 Aug 01 04:25 PM Campbell Bradley L President and CEO Jul 05 '24 Option Exercise 8.61 6,100 52,521 892,754 Jul 09 05:01 PM Campbell Bradley L President and CEO Jul 05 '24 Sale 10.00 6,100 61,029 886,654 Jul 09 05:01 PM Campbell Bradley L President and CEO Jul 01 '24 Option Exercise 8.61 1,400 12,054 888,054 Jul 03 04:22 PM Campbell Bradley L President and CEO Jul 01 '24 Sale 10.00 1,400 14,003 886,654 Jul 03 04:22 PM Campbell Bradley L President and CEO Jun 03 '24 Option Exercise 8.61 7,500 64,575 894,154 Jun 05 04:35 PM Campbell Bradley L President and CEO Jun 03 '24 Sale 10.00 7,500 75,000 886,654 Jun 05 04:35 PM Campbell Bradley L President and CEO May 01 '24 Option Exercise 8.61 7,500 64,575 894,154 May 03 05:21 PM Campbell Bradley L President and CEO May 01 '24 Sale 10.07 7,500 75,524 886,654 May 03 05:21 PM Campbell Bradley L President and CEO Apr 01 '24 Option Exercise 8.61 7,500 64,575 894,154 Apr 03 06:14 PM Campbell Bradley L President and CEO Apr 01 '24 Sale 11.67 7,500 87,496 886,654 Apr 03 06:14 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
